V92™ Cellular Bone Matrix

V92™ Cellular Bone Matrix

The V92™ product line: V92™ and V92™-FC are viable allogeneic bone allografts intended for use in bone remodeling. The V92™ products are safe and non-immunogenic and provide an ideal alternative to autograft in a variety of orthopaedic and spine applications.

The V92™  cellular bone matrices are viable allogeneic bone allografts containing viable bone-derived cells. Each V92™ product contains the three key elements that are ideal for bone formation:

  • An osteoconductive three-dimensional scaffold with cortical and cancellous components.
  • A demineralized bone scaffold with osteoinductive potential which provides exposure of signaling molecules and bone morphogenetic proteins.1
  • Bone-derived cells to support osteogenic healing processes.

The V92™  product line is prepared with a novel DMSO-free cryoprotectant, which provides dependable cell identity and the ability to sustain cell viability post-thaw. Final preparation of the cell and bone components yields a product that provides osteoconductive, osteoinductive, and osteogenic properties to enhance the patients’s innate healing response

Key Features

  • Two unique scaffold blends for optimal handling characteristics: V92™ and V92™-FC
  • Proprietary, optimized bone microparticulate size range of 100-300 μm.2
  • Novel DMSO-free cryoprotectant, with no rinsing and decanting steps required prior to use.
  • Average cell viability of the cell component exceeds 80% post-thaw.3
  • Minimum of 150,000 viable cells per cc of allograft post-thaw.3
  • Convenient handling and preparation in the OR, with total preparation time on the back table less than 20 minutes.
  • Four (4) hour working window for implantation after thaw without loss of cell viability.
  • Product shelf-life is two (2) years from date of processing when stored at -65°C or colder.
  1. Gruskin, E. et.al., Demineralized bone matrix in bone repair: history and use. Advanced Drug Delivery Reviews, 2012. 64:1063-1077.
  2. Malinin, T.I., et. al., Particulate bone allograft incorporation in regeneration of osseous defects; importance of particle sizes. The Open Orthopeadics Journal, 2007. 1:19-24.
  3. Data on file at Vivex Biomedical, Inc.

If you are a surgeon and would like more information or to book a case using the PRESERVE™ V92™ Cellular Bone Matrix, please enter your name and office phone number below.

Name

Email

Office Phone Number

Message

Not all product available for sale in all markets.  To determine availability in your marketplace, please contact your local Paragon 28 representative or email info@paragon28.com.